Q2 2026 saw 16% net sales growth, led by BD and Wound Management, with revenue at 57.1 MSEK and improved EBITDA. A new long-term BD agreement and strong partner pipeline support strategic growth, while cash flow and liquidity remain robust.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.